CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 163 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00747643
NCT00747643N/ACompleted
CompareCT.gov

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 5, 2008·Updated Dec 16, 2013

In Brief

A clinical study evaluating varenicline and placebo for Tobacco Dependence. Completed, enrolled 163 participants across 1 site.

Detailed Summary

The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline would change the response to smoking and the desire for cigarettes when compared to an inactive placebo control. This was not a quit smoking treatment study, and participants were not asked or required to stop smoking while in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Dependence
CountriesUnited States
CollaboratorsPfizer

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 5, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.8 years ago

Interventions

vareniclinedrug

Participants in this group received varenicline according to the schedule in the Arm Description.

placebodrug

Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.